索引超出了数组界限。 文章摘要
|本期目录/Table of Contents|

[1]李旭,赵兴胜.射血分数降低的心力衰竭药物治疗进展[J].国际心血管病杂志,2025,01:13-16.
点击复制

射血分数降低的心力衰竭药物治疗进展(PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2025年01期
页码:
13-16
栏目:
综述
出版日期:
2025-01-25

文章信息/Info

Title:
-
作者:
李旭; 赵兴胜
014060 包头医学院（李旭）；010010 呼和浩特，内蒙古自治区人民医院心内科（赵兴胜）
Author(s):
-
关键词:
射血分数降低的心力衰竭; 药物治疗; 心力衰竭
Keywords:
-
分类号:
-
DOI:
10.3969/j.issn.1673-6583.2025.01.004
文献标识码:
-
摘要:
射血分数降低的心力衰竭（HFrEF）严重影响患者生活质量与生存率。目前血管紧张素受体脑啡肽酶抑制剂、钠-葡萄糖共转运蛋白2抑制剂、可溶性鸟苷酸环化酶刺激剂、正性肌力药物Omecamtivmecarbil、铁剂及盐酸曲恩汀等药物在HFrEF的治疗中发挥重要作用，其中部分药物已广泛应用，部分尚处于研究阶段。随着研究深入，HFrEF的药物治疗方案有望不断优化，为改善患者的预后和生活质量带来更多可能。
Abstract:
-

参考文献/References

[1] Hao G, Wang X, Chen Z, et al. Prevalence of heart failure and left ventricular dysfunction in China: the China Hypertension Survey, 2012–2015[J]. Eur J Heart Fail, 2019, 21(11):1329-1337.
[2] Savarese G, Becher PM, Lund LH, et al. Global burden of heart failure: a comprehensive and updated review of epidemiology[J]. Cardiovasc Res, 2023, 118(17):3272-3287.
[3] 心血管健康联盟, 中国老年医学学会心电与心功能分会, 心衰中心联盟专家委员会. 中国心衰中心联盟心力衰竭医疗质量报告（2022年）[J]. 中华全科医师杂志, 2023, 22(6):557-568.
[4] McMurray JJV, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure[J]. N Engl J Med, 2014, 371(11):993-1004.
[5] Velazquez EJ, Morrow DA, DeVore AD, et al. Angiotensin-neprilysin inhibition in acute decompensated heart failure[J]. N Engl J Med, 2019, 380(6):539-548.
[6] Jering KS, Claggett B, Pfeffer MA, et al. Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE-MI):design and baseline characteristics[J]. Eur J Heart Fail, 2021, 23(6):1040-1048.
[7] Martens P, Nuyens D, Rivero-Ayerza M, et al. Sacubitril/valsartan reduces ventricular arrhythmias in parallel with left ventricular reverse remodeling in heart failure with reduced ejection fraction[J]. Clin Res Cardiol, 2019, 108(10):1074-1082.
[8] 中华医学会心血管病学分会, 中国医师协会心血管内科医师分会, 中国医师协会心力衰竭专业委员会, 等. 中国心力衰竭诊断和治疗指南2024[J]. 中华心血管病杂志, 2024, 52(3):235-275.
[9] 付祥雯, 孙慧. 钠-葡萄糖共转运蛋白2抑制剂在射血分数保留的心力衰竭治疗中的应用[J]. 国际心血管病杂志, 2024, 51(3):156-159.
[10] Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes[J]. N Engl J Med, 2015, 373(22):2117-2128.
[11] Kosiborod M, Cavender MA, Fu AZ, et al. Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study (comparative effectiveness of cardiovascular outcomes in new users of sodium-glucose cotransporter-2 inhibitors)[J]. Circulation, 2017, 136(3):249-259.
[12] Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes[J]. N Engl J Med, 2019, 380(4):347-357.
[13] Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes[J]. N Engl J Med, 2017, 377(7):644-657.
[14] McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction[J]. N Engl J Med, 2019, 381(21):1995-2008.
[15] Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure[J]. N Engl J Med, 2020, 383(15):1413-1424.
[16] Butler J, Jones WS, Udell JA, et al. Empagliflozin after acute myocardial infarction[J]. N Engl J Med, 2024, 390(16):1455-1466.
[17] Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American college of cardiology/American heart association joint committee on clinical practice guidelines[J]. Circulation, 2022, 145(18):e895-e1032.
[18] Armstrong PW, Pieske B, Anstrom KJ, et al. Vericiguat in patients with heart failure and reduced ejection fraction[J]. N Engl J Med, 2020, 382(20):1883-1893.
[19] Teerlink JR, Diaz R, Felker GM, et al. Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure[J]. N Engl J Med, 2021, 384(2):105-116.
[20] von Haehling S, Ebner N, Evertz R, et al. Iron deficiency in heart failure: an overview[J]. JACC Heart Fail, 2019, 7(1):36-46.
[21] Kalra PR, Cleland JGF, Petrie MC, et al. Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial[J]. Lancet, 2022, 400(10369):2199-2209.
[22] Mentz RJ, Garg J, Rockhold FW, et al. Ferric carboxymaltose in heart failure with iron deficiency[J]. N Engl J Med, 2023, 389(11):975-986.
[23] McDonagh TA, Metra M, Adamo M, et al. 2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure[J]. Eur Heart J, 2023, 44(37):3627-3639.
[24] Lu J, Pontré B, Pickup S, et al. Treatment with a copper-selective chelator causes substantive improvement in cardiac function of diabetic rats with left-ventricular impairment[J]. Cardiovasc Diabetol, 2013, 12:28.
[25] Crystal P. Copper-boosting agent promising for low ejection fraction heart failure—early-phase study analysis suggests potential for remodeling[N]. Med Page Today, 2023-10-10.

备注/Memo

备注/Memo:
通信作者：赵兴胜， E-mail：zhaoxs1121@163.com
更新日期/Last Update: 2025-02-10